NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of canakinumab for treating systemic juvenile idiopathic arthritis. If, after doing this, organisations still wish to consider canakinumab for treating systemic juvenile idiopathic arthritis, they should follow the advice set out in the Department of Health's Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance, which outlines the approach that should be adopted in circumstances in which NICE guidance is unavailable.
NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.
For information about NICE guidance that has been issued or is in development, see the NICE website.
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. NICE technology appraisal guidance 238 (2011).
© National Institute for Health and Care Excellence 2013. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.